Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial

被引：0

作者：

Ahn, M. -J. ^{[1
]}

Delmonte, A. ^{[2
]}

Ghosh, S. ^{[3
]}

Hochmair, M. ^{[4
,5
]}

Yang, T. -Y. ^{[6
]}

Yang, J. C. -H. ^{[7
,8
]}

Han, J. -Y. ^{[9
]}

Hansen, K. Holmskov ^{[10
]}

Wu, Y. ^{[11
]}

Wan, Y. ^{[11
]}

Lin, H. M. ^{[11
]}

Kretz, J. ^{[12
]}

Hupf, B. ^{[11
]}

Kurec, A. M. ^{[13
]}

Churchill, E. N. ^{[14
]}

Fram, R. J. ^{[11
]}

Cabasag, C. J. ^{[15
]}

Goriya, V. ^{[16
]}

Zhao, Y. ^{[17
]}

Gemmen, E. ^{[18
]}

Campelo, M. R. Garcia ^{[19
,20
]}

机构：

[1] Sungkyunkwan Univ, Dept Med Oncol, Samsung Med Ctr, Div Hematol,Sch Med, Seoul, South Korea

[2] IRCCS Ist Romagnolo Studio Tumori Dino Amadori I, Cesena, Italy

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria

[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria

[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan

[7] Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[9] Natl Canc Ctr, Goyang, South Korea

[10] Odense Univ Hosp, Odense, Denmark

[11] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[12] Takeda Pharmaceut Int AG, Glattpark Opfikon Zurich, Zurich, Switzerland

[13] Takeda Pharmaceut Int Singapore Emerging Markets, Singapore, Singapore

[14] Takeda Pharmaceut USA Inc, Lexington, MA USA

[15] IQVIA RDS France, Courbevoie, France

[16] IQVIA RDS France, Courbevoie, France

[17] IQVIA RDS Shanghai Co Ltd, Shanghai, Peoples R China

[18] IQVIA Falls Church, Falls Church, VA USA

[19] Univ Hosp Coruna, Dept Med Oncol, La Coruna, Spain

[20] Biomed Res Inst INIBIC A Coruna, La Coruna, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Brigatinib; ALK plus NSCLC; ALK TKI;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.12B.03

引用

页码：S200 / S200

页数：1

共 50 条

[21] Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L
Camidge, D. Ross
Kim, H. Ryun
Ahn, M. J.
Yang, James Ch.
Han, J. -Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Campelo, M. R. Garcia
Kim, D. -W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A. I.
Thomas, M.
Gettinger, S. N.
Tiseo, M.
Liu, Y.
Zhang, P.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E27 - E27
[22] Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
Camidge, D. R.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[23] Brigatinib vs crizotinib in the phase 3 ALTA-1L trial: Updated results
Griesinger, F.
Kim, H. R.
Ahn, M. -J.
Yang, J. C.
Han, J. -Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D. -W.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Lin, H.
Liu, Y.
Zhang, P.
Popat, S.
Camidge, D. R.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 142 - 142
[24] Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
Califano, R.
Hochmair, M. J.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Ghosh, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2019, 30 : 41 - 41
[25] Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC
Gupta, Neeraj
Reckamp, Karen L.
Camidge, David R.
Kleijn, Huub J.
Ouerdani, Aziz
Bellanti, Francesco
Maringwa, John
Hanley, Michael J.
Wang, Shining
Zhang, Pingkuan
Venkatakrishnan, Karthik
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (05): : 1143 - 1154
[26] Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK plus NSCLC
Schmid, S.
Chotai, S.
Cheng, S.
Zhan, L.
Balaratnam, K.
Khan, K.
Patel, D.
Brown, M. C.
Xu, W.
Moriarty, P.
Kaidanovich-Beilin, O.
Shepherd, F. A.
Sacher, A.
Leighl, N.
Bradbury, P.
Liu, G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1088 - S1088
[27] Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
Tiseo, M.
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A. I.
Gettinger, S. N.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, R.
ANNALS OF ONCOLOGY, 2022, 33 : S44 - S45
[28] Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L)
Garcia Campelo, Maria Rosario
Lin, Huamao M.
Zhu, Yanyan
Perol, Maurice
Jahanzeb, Mohammad
Popat, Sanjay
Zhang, Pingkuan
Camidge, D. Ross
LUNG CANCER, 2021, 155 : 68 - 77
[29] Systemic and Intracranial Efficacy of Brigatinib vs.Crizotinib: Updated Results from the ALTA-1L Trial
Popat, S.
Kim, H. R.
Ahn, M. -J.
Yang, James C. H.
Han, J. -Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Campelo, M. R. Garcia
Kim, D. -W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Lin, H.
Liu, Y.
Zhang, P.
Camidge, D. R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S9
[30] Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK plus cohort updated biomarker analyses
Gadgeel, S. M.
Yan, M.
Paul, S. M.
Mathisen, M.
Mocci, S.
Assaf, Z. J.
Patel, R.
Sokol, E. S.
Mok, T.
Peters, S.
Paz-Ares, L.
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2020, 31 : S841 - S841

← 1 2 3 4 5 →